...
首页> 外文期刊>Internal medicine. >Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer
【24h】

Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer

机译:通过免疫检查点抑制剂治疗在胰岛素相关抗原-2自身抗癌患者中诱导的非胰岛素依赖性糖尿病,其具有晚期胃癌

获取原文

摘要

A 70-year-old man with insulinoma-associated antigen-2 autoantibodies developed diabetes mellitus (DM) without ketoacidosis after starting nivolumab to treat advanced gastric cancer. He subsequently exhibited preserved insulin-secretion capacity for over one year. Immune checkpoint inhibitors (ICIs) infrequently cause type 1 DM associated with the rapid loss of insulin secretion and ketoacidosis as an immune-related adverse event. ICIs may also cause non-insulin-dependent DM by inducing insulin resistance if there is islet autoantibody-related latent beta-cell dysfunction. The present case highlights the importance of testing blood glucose levels regularly to diagnose DM in patients treated with ICIs, even if they do not have diabetic ketoacidosis.
机译:一个70岁的男子患有胰岛素相关的抗原-2自身抗体在开始Nivolumab治疗晚期胃癌后发育糖尿病(DM),在没有酮症中的糖尿病没有酮症中毒。他随后表现出保存的胰岛素分泌能力超过一年。免疫检查点抑制剂(ICIS)不经常引起与胰岛素分泌和酮症中的快速丧失相关的1 dM,作为免疫相关的不良事件。如果存在胰岛素的自身抗体相关的潜伏β细胞功能障碍,ICIS还可能导致非胰岛素依赖性DM。本案例突出了定期测试血糖水平的重要性,以诊断用ICIS治疗的患者DM,即使它们没有糖尿病酮症病症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号